Ophthalmic Drugs Market By Type (Prescription Ophthalmic Drugs, OTC), By Therapeutics (Glaucoma, Retinal Disorder, Dry Eye, Allergic Conjunctivitis), By End User (Hospitals, Eye Clinics, Diagnostic Centers, Patients), Industry Size, Growth, Share And Forecast To 2022
The global ophthalmic drugs market is expected to grow at a CAGR of 7% during 2015-2022 and is estimated to be approximately $XX billion at the end of the forecasted period i.e. by 2022. The market is driven by various factors which include increase prevalence of eye related disorders such as glaucoma and cataract aging population, regulatory approvals to new drugs and devices, new technologies such as focus on combining drugs and device therapies and increasing economic factors such as rise in disposable income and health expenditure in emerging countries such as India and China. The market is expected to grow at good growth rate due to growing awareness especially in the emerging and underdeveloped countries. However, factors such as expiration of patents, drying pipelines and major slowdowns in economies may hamper the market growth.
However, factors such as expiration of patents, drying pipelines and major slowdowns in economies may hamper the market growth.
Market segment insight
The application market for ophthalmic drugs market is segmented as follows: Based on drugs for glaucoma, retinal disorder, dry eye, allergic conjunctivitis, inflammation and conjunctivitis. The end users include hospitals, eye clinics, diagnostic centers and patients. During the year 2015 retinal disorders and glaucoma segments are expected to have largest market share of all the other segments present in the market and it is expected that this segment would be maintaining its dominance in the industries.
Regional insight
The major geographies include North America, Europe, Asia-Pacific and rest of the world. North America is the largest market followed by Europe and Asia pacific. The North American market is driven high awareness, availability of drugs due to presence of major players. Better regulatory policies have led to increased trust in the drugs. Asia Pacific market to have high growth rate driven by strong markets in China and India.
Competitive insight
Market includes top players such as Abbot Laboratories, ltd, Allergan Inc, Roche, Pfizer, Novartis, Bayer, Senju, Johnson and Johnson and Santen. The market is working on developing new combination drugs. Whereas players in the emerging countries are more focused on generic drugs. Increase in the number of market players and adoption of more advanced methods as compared to the conventional ones are the key market trend of the industry.
Reasons for buying the report
- This report provides a detailed study of current trends in the ophthalmic drugs industry, key growth drivers, and restraints.
- It provides market forecast for the next 7 years (2015-2022) assessed on the basis of market growth.
- The report also includes analysis of recent technological developments in the ENT devices market, analysis of key market players and the key winning strategy adopted and predictive analysis.
- The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
- The report tracks and analyse the changing market dynamics.
- The report also talks about emerging opportunities in the market and the future impact of major drivers and restraints of the market.
- The report also provides extensive analysis with respect to key product segments.
- The analysis in the report will help in making effective business decisions.
- It provides analysis through distinctive graphs and charts and analyses strengths, weakness, opportunities and threats of major market players.
1. METHODOLOGY & SCOPE 10
1.1. Research Methodology 10
1.2. Research Scope & Assumptions 10
1.3. List of Data Sources 10
2. EXECUTIVE SUMMARY 10
2.1. Global Opthalmic Drugs market – Industry summary & key buying criteria 10
2.2. Global Opthalmic Drugs market – industry outlook 10
3. MARKET SEGMENTATION 10
3.1. Market size and growth prospects 2012-2022 10
3.2. Global Opthalmic Drugs industry value chain analysis 10
3.3. Vendor Landscape 10
4. GLOBAL OPTHALMIC DRUGS MARKET DYNAMICS 10
4.1. Market driver analysis 10
4.1.1. Global increase in elderly population giving rise to ophthalmology market 10
4.1.2. Technological advancement 10
4.1.3. Innovation giving rise to ophthalmology drug market 10
4.1.4. Global increase in prevalence rates of eye diseases 10
4.1.5. Global increase in healthcare expenditure 10
4.2. Market restraint analysis 10
4.2.1. Major drugs going off patent is affecting the growth of ophthalmology market 10
4.2.2. Drying pipelines is a concern for major players 10
4.3. Key opportunities prioritized 10
4.3.1. Increased awareness 10
4.3.2. Emerging Markets 10
5. INDUSTRY ANALYSIS – PORTER’S 10
5.1. Global Opthalmic Drugs market industry– PESTEL analysis 10
6. GLOBAL OPHTHALMIC DRUGS MARKET BY TYPE 2012 - 2022 ($ BILLION) 10
6.1. Global Prescription ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
6.2. Global OTC (over the counter drugs) ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
7. GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTICS 2012 - 2022 ($ BILLION) 11
7.1. Global Glaucoma ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
7.2. Global retinal disorder ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
7.3. Global Dry eye ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
7.4. Global Allergic conjunctivitis ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
8. GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2012 - 2022 ($ BILLION) 11
8.1. Global Hospitals ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
8.2. Global Eye clinics ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
8.3. Global Diagnostic centers ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
8.4. Global Patients ophthalmic drugs market 2012 - 2022 ($ BILLION) 11
9. GLOBAL OPTHALMIC DRUGS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 11
9.1. Global Opthalmic Drugs market volume share by region 2012 – 2022 ($ BILLION) 11
9.2. North America 11
9.2.1. North America market estimates and forecast 2012 – 2022 ($ BILLION) 11
9.2.2. North America market estimates and forecast by region 2012 – 2022 ($ BILLION) 11
9.2.3. North America market estimates and forecast by application 2012 – 2022 ($ BILLION) 12
9.2.3.1. US 12
9.2.3.1.1. US market estimates and forecast 2012 – 2022($ BILLION) 12
9.2.3.1.2. U.S. market estimates and forecast by application 2012 – 2022($ BILLION) 12
9.2.3.2. Canada 12
9.2.3.2.1. Canada market estimates and forecast 2012 – 2022 ($ BILLION) 12
9.2.3.2.2. Canada market estimates and forecast by application 2012 – 2022 ($ BILLION) 12
9.2.3.3. Mexico 12
9.2.3.3.1. Mexico market estimates and forecast, 2012 – 2022($ BILLION) 12
9.2.3.3.2. Canada market estimates and forecast by application 2012 – 2022 ($ BILLION) 12
9.3. Europe 12
9.3.1. Europe market estimates and forecast 2012–2022($ BILLION) 12
9.3.2. Europe market estimates and forecast by region 2012–2022 ($ BILLION) 12
9.3.3. Europe market estimates and forecast by application 2012 – 2022 ($ BILLION) 12
9.3.3.1. Germany 12
9.3.3.1.1. Germany market estimates and forecast 2012 – 2022 ($ BILLION) 12
9.3.3.1.2. Germany market estimates and forecast by applicatio 2012 – 2022($ BILLION) 12
9.3.3.2. UK 12
9.3.3.2.1. UK market estimates and forecast 2012 – 2022 ($ BILLION) 12
9.3.3.2.2. market estimates and forecast by application 2012 – 2022 ($ BILLION) 13
9.3.3.3. Russia 13
9.3.3.3.1. Russia market estimates and forecast 2012 – 2022 ($ BILLION) 13
9.3.3.3.2. Russia market estimates and forecast by applicatioN 2012 – 2022 ($ BILLION) 13
9.4. Asia Pacific 13
9.4.1. Asia Pacific market estimates and forecast 2012 – 2022 ($ BILLION) 13
9.4.2. Asia Pacific market estimates and forecast by region 2012 – 2022 ($ BILLION) 13
9.4.3. Asia Pacific market estimates and forecast by application 2012 – 2022 ($ BILLION) 13
9.4.3.1. China 13
9.4.3.1.1. China market estimates and forecast 2012 – 2022 ($ BILLION) 13
9.4.3.1.2. China market estimates and forecast by application 2012 – 2022 ($ BILLION) 13
9.4.3.2. India 13
9.4.3.2.1. India market estimates and forecast 2012 – 2022 ($ BILLION) 13
9.4.3.2.2. India market estimates and forecast by application 2012 – 2022 ($ BILLION) 13
9.4.3.3. South Korea 13
9.4.3.3.1. South Korea market estimates and forecast 2012 – 2022 ($ BILLION) 13
9.4.3.3.2. South Korea market estimates and forecast by application 2012 – 2022 ($ BILLION) 13
9.5. Middle East & Africa 14
9.5.1. Middle East & Africa market estimates and forecast 2012 – 2022 ($ BILLION) 14
9.5.2. Middle East & Africa market estimates and forecast by application 2012 – 2022 ($ BILLION) 14
9.6. Central &South America 14
9.6.1. Central & South America market estimates and forecast 2012 – 2022 ($ BILLION) 14
9.6.2. Central & South America market estimates and forecast by application 2012 – 2022 ($ BILLION) 14
9.6.2.1. Brazil 14
9.6.2.1.1. Brazil market estimates and forecast 2012 – 2022 ($ BILLION) 14
9.6.2.1.2. Brazil market estimates and forecast by application 2012 – 2022 ($ BILLION) 14
10. COMPETITIVE LANDSCAPE 15
10.1. Abbot Laboratories 15
10.1.1. COMPANY OVERVIEW 15
10.1.2. FINANCIAL PERFORMANCE 15
10.1.3. PRODUCT BENCHMARKING 15
10.1.4. STRATEGIC INITIATIVES 15
10.2. Allergan Inc 15
10.2.1. COMPANY OVERVIEW 15
10.2.2. FINANCIAL PERFORMANCE 15
10.2.3. PRODUCT BENCHMARKING 15
10.3. Johnson and Johnson 15
10.3.1. COMPANY OVERVIEW 15
10.3.2. FINANCIAL PERFORMANCE 15
10.3.3. PRODUCT BENCHMARKING 15
10.4. Bayer 15
10.4.1. COMPANY OVERVIEW 15
10.4.2. FINANCIAL PERFORMANCE 15
10.4.3. PRODUCT BENCHMARKING 15
10.5. Valeant 15
10.5.1. COMPANY OVERVIEW 15
10.5.2. FINANCIAL PERFORMANCE 15
10.5.3. PRODUCT BENCHMARKING 15
10.6. Regeneron 15
10.6.1. COMPANY OVERVIEW 15
10.6.2. FINANCIAL PERFORMANCE 15
10.6.3. PRODUCT BENCHMARKING 15
10.7. Akorn 15
10.7.1. COMPANY OVERVIEW 15
10.7.2. FINANCIAL PERFORMANCE 15
10.7.3. PRODUCT BENCHMARKING 15
10.8. Eyemed 15
10.8.1. COMPANY OVERVIEW 15
10.8.2. FINANCIAL PERFORMANCE 15
10.8.3. PRODUCT BENCHMARKING 15
10.9. Senju 15
10.9.1. COMPANY OVERVIEW 15
10.9.2. FINANCIAL PERFORMANCE 16
10.9.3. PRODUCT BENCHMARKING 16
10.10. Pfizer Inc 16
10.10.1. COMPANY OVERVIEW 16
10.10.2. FINANCIAL PERFORMANCE 16
10.10.3. PRODUCT BENCHMARKING 16
10.11. Roche holding AG 16
10.11.1. COMPANY OVERVIEW 16
10.11.2. FINANCIAL PERFORMANCE 16
10.11.3. PRODUCT BENCHMARKING 16
10.12. Santen pharmaceutical co. ltd 16
10.12.1. COMPANY OVERVIEW 16
10.12.2. FINANCIAL PERFORMANCE 16
10.12.3. PRODUCT BENCHMARKING 16
10.13. Merck & Co. 16
10.13.1. COMPANY OVERVIEW 16
10.13.2. FINANCIAL PERFORMANCE 16
10.13.3. PRODUCT BENCHMARKING 16
10.14. Novagali Pharma S.A. 16
10.14.1. COMPANY OVERVIEW 16
10.14.2. FINANCIAL PERFORMANCE 16
10.14.3. PRODUCT BENCHMARKING 16
10.15. Novartis AG 16
10.15.1. COMPANY OVERVIEW 16
10.15.2. FINANCIAL PERFORMANCE 16
10.15.3. PRODUCT BENCHMARKING 16
10.16. Cipla Pharmaceuticals 16
10.16.1. COMPANY OVERVIEW 16
10.16.2. FINANCIAL PERFORMANCE 16
10.16.3. PRODUCT BENCHMARKING 16
10.17. Sun Pharmaceuticals 16
10.17.1. COMPANY OVERVIEW 16
10.17.2. FINANCIAL PERFORMANCE 16
10.17.3. PRODUCT BENCHMARKING 16
10.18. GlaxoSmithKline 16
10.18.1. COMPANY OVERVIEW 16
10.18.2. FINANCIAL PERFORMANCE 17
10.18.3. PRODUCT BENCHMARKING 17
10.19. Eye Gate Pharmaceuticals 17
10.19.1. COMPANY OVERVIEW 17
10.19.2. FINANCIAL PERFORMANCE 17
10.19.3. PRODUCT BENCHMARKING 17
10.20. Lpath 17
10.20.1. COMPANY OVERVIEW 17
10.20.2. FINANCIAL PERFORMANCE 17
10.20.3. PRODUCT BENCHMARKING 17
TABLE 1 GLOBAL OPHTHALMIC DRUGS MARKET BY TYPE 2012 - 2022 ($ BILLION) 17
TABLE 2 GLOBAL PRESCRIPTION OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 3 GLOBAL OTC (OVER THE COUNTER DRUGS) OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 4 GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTICS 2012 - 2022 ($ BILLION) 17
TABLE 5 GLOBAL GLAUCOMA OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 6 GLOBAL RETINAL DISORDER OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 7 GLOBAL DRY EYE OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 8 GLOBAL ALLERGIC CONJUNCTIVITIS OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 9 GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2012 - 2022 ($ BILLION) 17
TABLE 10 GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 11 GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 17
TABLE 12 GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 18
TABLE 13 GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET 2012 - 2022 ($ BILLION) 18
FIGURE 1 GLOBAL OPTHALMIC DRUGS INDUSTRY MARKET SHARE 2012 - 2022 ($ BILLION) 18
FIGURE 2 MARKET SHARE BY REGIONS 18
FIGURE 3 UNITED STATES MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 4 CANADA MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 5 MEXICO MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 8 GERMANY MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 9 APAC MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 10 CHINA MARKET ESTIMATES AND FORECAST 2012 – 2022($ BILLION) 18
FIGURE 11 INDIA MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 12 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 13 CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
FIGURE 14 BRAZIL MARKET ESTIMATES AND FORECAST 2012 – 2022 ($ BILLION) 18
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)